Close this search box.

Multi-Omics Study of ME/CFS (MAESTRO)

The primary goal of this project is to complete our comprehensive analysis of the genome, methylome, miRnome, and their interactions in order to fill the gaps in our understanding of ME/CFS pathophysiology and to identify clinically useful biomarkers.

  • Alain Moreau, PhD
  • Identified 11 circulating microRNAs associated with PEM response and symptom severity
  • Developed a diagnostic test, the first of its kind for ME/CFS. 
  • Determined that the molecular stratification of ME/CFS patients along five clusters can predict the therapeutic response toward different pharmacological treatments.
  • Analyzed discordant identical twins (one having ME/CFS, the other being healthy) land discovered distinct DNA methylation profiles, which could explain specific symptoms associated with ME/CFS. 
  • Conducted neurocognitive evaluations prior and after the induction of PEM, and stratified ME/CFS patients into four clusters using a machine-learning method.
  • This project is now complete and the work continues through the REMEDIAL initiative.


Identifying ME/CFS biomarkers will aid in the development of disease risk prediction and improve the clinical stratification of symptomatic patients. Ultimately, the discovery of biomarkers may lead to diagnoses that are more accurate, disease prevention measures, and indications on how to treat ME/CFS effectively.

We also we intend to investigate specific targets to determine their clinical utility for the elaboration of novel therapeutic approaches to treat the main symptoms associated with ME/CFS (e.g., PEMS, POTS, sleep disturbances and fatigue). We intend to develop better clinical tools allowing clinicians to diagnose ME/CFS and select the best treatments to address their medical needs.



  • Deep phenotyping and longitudinal monitoring of PEM in severely ill patients
  • Genome-wide microRNA profiling to associate with PEM in discordant and concordant twins
  • DNA methylome (saliva) testing in discordant and concordant twins and across multiplex families
  • Whole-genome sequencing across multiplex families and unrelated cases.
Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

What are the advantages of giving from your Donor Advised Fund (DAF)?

  • Your gifts to your donor advised fund entitle you to an immediate income tax deduction at the time of contribution.
  • You avoid capital gains tax on appreciated assets you place in your donor advised fund.
  • Your fund’s investment gains accumulate tax free.
  • Funds are distributed to Open Medicine Foundation in your name and immediately put to use to support our worldwide research efforts.

How do I make a donation through my DAF?

Just click on the DAF widget below. It is simple and convenient to find your fund among the over 900 funds in our system.

Still can’t find your fund? 

  • Request a grant distribution through your Donor Advised Fund sponsor
  • Be sure to use OMF’s EIN #26-4712664
  • You can also designate OMF as a beneficiary for your Donor Advised Fund
  • Questions? Give us a call at 650-242-8669